The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes

被引:68
作者
Menendez, D [1 ]
Inga, A [1 ]
Resnick, MA [1 ]
机构
[1] NIEHS, Chromosome Stabil Sect, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA
关键词
D O I
10.1128/MCB.26.6.2297-2308.2006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human tumor suppressor p53 is a sequence-specific master regulatory transcription factor that targets response elements (REs) in many genes. p53 missense mutations in the DNA-binding domain are often cancer associated. As shown with systems based on the yeast Saccharomyces cerevisiae, p53 mutants can alter the spectra and intensities of transactivation from individual RE's. We address directly in human cells the relationship between changes in the p53 master regulatory network and biological outcomes. Expression of integrated, tightly regulated DNA-binding domain p53 mutants resulted in many patterns of apoptosis and survival following UV or ionizing radiation, or spontaneously. These patterns reflected changes in the spectra and activities of target genes, as demonstrated for P21, MDM2, BAX, and MSH2. Thus,as originally proposed for "master genes of diversity," p53 mutations in human cells can differentially influence target gene transactivation, resulting in a variety of biological consequences which, in turn, might be expected to influence tumor development and therapeutic efficacy.
引用
收藏
页码:2297 / 2308
页数:12
相关论文
共 66 条
[31]  
MCILWRATH AJ, 1994, CANCER RES, V54, P3718
[32]   Mechanisms of switching on p53: a role for covalent modification? [J].
Meek, DW .
ONCOGENE, 1999, 18 (53) :7666-7675
[33]   A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network [J].
Menendez, D ;
Krysiak, O ;
Inga, A ;
Krysiak, B ;
Resnick, MA ;
Schönfelder, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (05) :1406-1411
[34]   The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression [J].
Minsky, N ;
Oren, M .
MOLECULAR CELL, 2004, 16 (04) :631-639
[35]   Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations [J].
Nikolova, PV ;
Wong, KB ;
DeDecker, B ;
Henckel, J ;
Fersht, AR .
EMBO JOURNAL, 2000, 19 (03) :370-378
[36]  
Offer H, 2001, CANCER RES, V61, P88
[37]   The IARC TP53 database: New Online mutation analysis and recommendations to users [J].
Olivier, M ;
Eeles, R ;
Hollstein, M ;
Khan, MA ;
Harris, CC ;
Hainaut, P .
HUMAN MUTATION, 2002, 19 (06) :607-614
[38]   Decision making by p53: life, death and cancer [J].
Oren, M .
CELL DEATH AND DIFFERENTIATION, 2003, 10 (04) :431-442
[39]  
Prives C, 1999, J PATHOL, V187, P112
[40]   Comparison of apoptotic, necrotic and clonogenic cell death and inhibition of cell growth following camptothecin and X-radiation treatment in a human melanoma and a human fibroblast cell line [J].
Quto, SS ;
Ng, CE .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 49 (02) :167-175